EMA关于在COVID-19（冠状病毒）大流行期间临床试验管理指南译文双语

EMA Guidance on theManagement of Clinical Trials during the COVID-19 (Coronavirus) pandemic

EMA关于在COVID-19（冠状病毒）大流行期间

临床试验管理指南

中国医药创新促进会国际部翻译整理

Version 1 (20/03/2020)

第一版（2020年3月20日）

The EuropeanMedicines Agency (EMA), Good Clinical Practice (GCP) Inspectors Working Group,the Clinical Trials Facilitation and Coordination Group (CTFG, a working groupof the Heads of Medicines Agency (HMA)), the Clinical Trials Expert Group(CTEG, a working group of the European Commission representing EthicsCommittees and National Competent Authorities) and the European Commission (EC)acknowledge the impact of COVID-19 on the health system and broader society,and the impact it may have on clinical trials and trial participants[1].Extraordinary measures may need to be implemented and trials adjusted due toe.g. trial participants being in self-isolation/quarantine, limited access topublic places (including hospitals) due to the risk of spreading infections,and health care professionals being committed to critical tasks. Therefore,EMA, EC and HMA ply support the efforts of the GCP Inspectors' WorkingGroup for developing harmonised EU/EAA-level guidance to mitigate the negativeeffects of the COVID-19 pandemic on the conduct of clinical trials.

欧洲药品管理局（EMA）、欧盟药品临床质量管理规范（GCP）检查员工作组、临床试验促进和协调工作组（CTFG，隶属于药品监管机构负责人组织（HMA））、临床试验专家工作组（CTEG，隶属于欧盟委员会（EC），代表伦理委员会和国家主管当局）和EC认识到COVID-19对卫生系统及广大社会的影响，以及可能对临床试验和受试者造成影响。在诸如受试者处于自我隔离或隔离状态、因存在传播感染风险而无法进入公共场所（包括医院），以及医护人员执行严峻工作时，需要实施特殊手段并调整临床试验。因此，EMA、EC和HMA坚决支持GCP检查员工作组为制定统一的EU / EAA级指导方针以减轻COVID-19大流行对临床试验的负面影响而做出的努力。

The situationis evolving, and pragmatic actions may be required to deal with the challengesof conducting research, and in ensuring the rights, safety and wellbeing ofparticipants. The points mentioned below are intended to provide guidance forall parties involved in clinical trials during this time.

面对不断升级的疫情，需要采取务实的行动来应对临床试验过程中的挑战，并确保受试者的权利、安全和健康。以下要点旨在为疫情流行期间参与临床试验的各方提供指导。

Due to theurgency, this guidance is issued without prior public consultation. Thesponsors should note that due to the rapidly evolving situation further updatesto this guidance are possible and likely.

鉴于紧急情况，本指南的发布未事先征询公众意见。申办者应注意，由于疫情的迅速蔓延，本指南有可能会做出相应修订。

Sponsors and investigators need to take into account that theremight be specific national legislation and guidance in place, which they shouldconsult and which can be used to complement this guidance, or, with respect toparticular matters may take priority over these recommendations. This documentis however seeking to include most of the current guidance across Member Stateswith the aim to serve as an EU-level harmonised set of recommendations. Hence,this guidance is agreed by the Clinical Trials Expert Group (CTEG) of theEuropean Commission supported by the EMA, the Clinical Trials Facilitation andCoordination Group (CTFG) of the Heads of Medicines Agencies (HMA) and the GCPInspectors' Working Group coordinated by the EMA.

申办者和研究者应考虑到，可能有一些国家法律和指南已在实施，这些立法和指南应作为参考，并可用作对本指南的补充，或者就某些特定事项而言，优先遵循这些立法和指南。但是，该文件旨在囊括各成员国当前的大多数指南，以期在欧盟级别达成一致。因此，本指南经EC CTEG同意，并由EMA、HMA CTFG和EMA协调的GCP检查员工作组共同支持。

Introduction

I.前言

Variouschallenges exist which result in restrictions of visits to healthcarefacilities, increased demands on the health service and changes to trial staffavailability. Participants may also be required to self-isolate, whichintroduces difficulties for Investigators to maintain their medical oversight.These challenges could have an impact on the conduct of trials, such as the completionof trial assessments, completion of trial visits and the provision of InvestigationalMedicinal Products (IMPs).

当前临床试验中存在各种挑战，这些挑战导致了医疗机构的访视限制、医疗服务的需求增加以及执行试验人员的不稳定性。受试者还可能被要求进行自我隔离，给研究者进行医疗监督带来了困难。这些挑战可能会影响试验的进行，例如完成试验评估，完成访视和提供试验用药品（Investigational Medicinal Products，以下简称IMPs）。

The impact ofCOVID-19 on ongoing trials, on opening a new trial site in an existing trial,ongoing recruitment and continued involvement of participants in the trial, oron starting of new trials needs to be considered. This evaluation should takeinto account national recommendations including travel restrictions andconfinements of trial participants and trial staff and the availability oftrial staff to perform visits, enter data in the Case Report Form (CRF), notify serious adverse events and, more generally, follow the protocol.The ability to confirm eligibility and to conduct key safety assessments andtrial evaluation is of particular importance. Actions should be proportionateand based on benefit-risk considerations, on contingency provisions takennationally and locally by the authorities with priority given to the impact onthe health and safety of the trial participant. Where a trial participant isunable to attend the site, other measures, such as home nursing, if possiblegiven social distancing needs, or contact via phone or telemedicine means, maybe required to identify adverse events and ensure continuous medical care andoversight. However, the limitations and risks of such methods and therequirements for data protection should be taken into account and suchalternative arrangements need to be adequately documented.

对正在进行的临床试验、在现有试验和招募过程中开设新的试验机构、继续招募受试者，或者开始新试验，都需要考虑COVID-19的影响。该评估应考虑国家建议，包括旅行限制、受试者和试验人员的限制以及试验人员是否能够进行访视、在病例报告表（Case Report Form，CRF）中输入数据、通报严重不良事件、以及更通俗地说，遵循方案。具备确认进行关键安全性评估和试验评估的资格和能力尤其重要。采取的行动应适当，并基于利益风险的考虑，当局在全国和地方采取的应急规定，应优先考虑对受试者的健康和安全的影响。如果受试者无法进入试验机构，则可能需要采取其他措施，例如考虑到社区隔离的需求，如有可能，可进行家庭护理，或通过电话或远程医疗手段进行联系，以识别不良事件并确保持续的医疗护理和监督。但是，应考虑到这种方法的局限性和风险以及对数据保护的要求，并且这些替代性安排也必须得到充分的记录。

Initiating newtrials

开展新临床试验

The feasibilityof starting a new clinical trial or including new trial participants in anongoing trial should be critically assessed by sponsors.

申办者应严格评估开始新临床试验或在正在进行的试验中招募新的受试者的可行性。

Changes in ongoing trials

进行中的临床试验的变更

The sponsorsshould consider in their risk assessment whether the following measures couldbe the most appropriate during COVID-19. Measures should generally be agreedwith investigators and could be:

申办者应在其风险评估中考虑在COVID-19期间以下措施是否最合适。通常应与研究者达成共识，可以是：

•Conversion of physical visits intophone or video visits, postponement or complete cancellation of visits toensure that only strictly necessary visits are performed at sites;

•将实际访视转换为电话访视或视频访视，推迟或取消访视，以确保仅严格且必要的访视在机构内执行；

•A temporary halt of the trial at someor all trial sites;

•在某些或所有试验机构暂停试验；

•Suspension or slowing down ofrecruitment of new trial participants;

•暂停或延缓新受试者的招募；

•Extension of the duration of the trial;

•延长试验期限；

•Postponement of trials or activation ofsites that have not yet been initiated;

•推迟试验或激活尚未启动的机构；

•Closing of sites. In case it is notfeasible for a site to continue participation at all, the sponsor shouldconsider if the trial site should be closed and how this can be done withoutcompromising safety and well-being of patients already participating and datavalidity;

•关闭试验机构。如果某个机构无法继续参与，则申办者应考虑将其关闭，以及如何在不损害受试者安全和健康以及数据有效性的前提下进行；

•If unavoidable (it should be justifiedthat this is a truly exceptional situation based on the personal risk-benefitratio for the individual trial participant), transfer of participants toinvestigational sites away from risk zones, or closer to their home, to sitesalready participating in the trial, or new ones could occur. Initiation of newtrial sites is generally not expected in the current situation unless no othersolution exists for the trial participant. If there is an urgent need to open anew trial site for critical trial visits for example outside the hospital, thismay be implemented as an urgent safety measure (USM) first,with a substantial amendment (SA) application submitted lateras for the approval and initiation of an additional site later. The exceptionalsituation could involve e.g. a trial participant who urgently needs to stay inthe trial and for whom no other sites are available. In such cases, it isimportant that trial participants as well as investigators (both receiving andsending) are in agreement about the transfer and that the receiving site hasthe possibility to access previously collected information/collected data forthe trial participant and that any eCRF can be adjusted accordingly to allowthe receiving site to enter new data. The impact on trial participants shouldbe considered and arrangements made to e.g. appropriate transportation;transport;

•如果必须关闭试验机构（此为基于受试者个人风险收益比而判断的极其特殊的情况），则应将受试者转移到远离风险区或离家较近的研究机构，或者转移到已经开展试验的机构中，亦或是可能出现的新试验机构中。在当前情况下，通常不希望启动新的试验机构，除非没有其他解决方案。如果需要紧急启动新的试验机构进行关键性试验访视，例如在院外访视，则可以先作为紧急安全措施（urgent safety measure，USM）实施，然后提交重大修改（substantial amendment，SA）申请。特殊情况可能涉及迫切需要继续参加试验且没有其他机构可用的受试者。在这种情况下重要的是，受试者和（接收和派遣）研究者都应就转移达成一致，并且接收机构可以访视之前收集的受试者信息/数据，允许接收机构对任何电子病历报告表进行相应地调整和输入新数据。应考虑转移过程对于受试者的影响并作出安排，例如合适的运输、交通等。

•There may be a need for criticallaboratory tests, imaging or other diagnostic test to be performed for patientsafety. In case the trial participant cannot reach the site to have theseperformed, it is acceptable that laboratory, imaging or other diagnostic testsare done at a local laboratory (or relevant clinical facility for other tests)authorised/certified (as legally required nationally) to perform such testsroutinely (e.g. blood cell count, liver function test, X-ray, ECG etc.), ifthis can be done within local restrictions on social distancing. The sitesshould inform the sponsor about such cases. Local analysis can be used forsafety decisions. If this is a trial endpoint and the samples cannot be shippedto the central lab, analysis should be performed locally and then explained,assessed and reported in the clinical study report following ICH E3.

•为了患者的安全，可能需要进行关键的实验室检查，影像检查或其他诊断检查。如果受试者无法到达现场进行检查，则可以在授权/有资质（符合国家法律要求）的地方实验室（或可进行其他检查的相关临床设施）中进行实验室、影像学或其他诊断检查。如果在当地社区隔离限制条件下可以操作，则应例行此类检查（例如血细胞计数，肝功能检查，X射线，ECG等）。机构应将此类情况通知申办者。地方分析可用于安全决策。如果这是试验终点，并且样品无法分发到中央实验室，则应在当地进行分析，然后在遵循ICH E3指导原则的情况下在临床研究报告中进行解释、评估。

The changesabove may also be initiated by the investigator sites contacting the sponsor.There might also be cases where the current principal investigator (PI) of asite is indisposed for a period and may need to delegate parts of his/herduties temporarily to e.g. a sub-investigator. Any permanent changes in PIshould be submitted to the National Competent Authority (NCA) and EthicsCommittees as appropriate.

上述更改也可以由研究者所在机构联系申办者发起。在某些情况下，某一地区的主要研究者（PI）可能会在一段时间内无法进行试验，并且可能需要副研究者暂时代理其部分职责。如需永久变更PI，应酌情提交给国家主管当局（National Competent Authority，NCA）和道德委员会。

When changes inongoing trials are considered, the overall well-being and best interests of theparticipant should be also considered, for example in trials for patients withlife-threatening or severely debilitating conditions, when participants requireto stay on trial treatment. In cases, when trial halt, even if temporary only,can potentially compromise the overall well-being and best interest of trialparticipants, all measures need to be considered and taken to avoid this.

变更正在进行的试验，还应考虑受试者的整体健康和最大利益，例如存在有生命危险或严重衰弱的患者的试验，受试者需要继续接受试验治疗。在某些情况下，即使只是暂时停止试验，也有可能损害受试者的整体生命健康和最大利益时，则应考虑并采取一切措施来避免这种情况。

Changes shouldbe well balanced, taking into account in particular the legitimate interest oftrial sites in avoiding further burden in terms of time and staffing during theCOVID-19 pandemic.

应当充分平衡考虑各种变化，尤其是试验机构的合法利益，以避免在COVID-19大流行期间造成时间和人员的进一步负担。

Please notethat prospective protocol waivers remain unacceptable and that patients shouldnot be included in trials without proper eligibility assessment, includingperformance of planned tests, and written informed consent according tonational laws and regulations.

请注意，预期的方案豁免仍不适用，并且在没有进行适当的资格评估（包括进行计划的测试，以及符合国家法律和法规的书面知情同意）情况下，不应将患者纳入试验。

Compliance withthe trial protocol should be ensured to such an extent that an ongoingbenefit-risk assessment for the clinical trial and its participants is stillpossible. The impact of protocol changes on clinical data interpretabilityneeds to be properly assessed by the sponsor and the overall evidencegeneration package could be subsequently discussed within scientific advicewith regulatory authorities. Guidance on methodological considerations is beingprepared by the CHMP Biostats working party and will be linked to this documentonce finalized.

应严格执行试验方案，以确保正在进行的临床试验及受试者的利益风险评估不受影响。申办者应相应评估方案变更对临床数据解读的影响，随后可与监管机构对所有证据资料进行科学的建议和讨论。欧盟人用药委员会(CHMP)的生物统计工作组正在筹备方法学的指导意见，定稿后将附在该文件链接中。

Risk assessment

风险评估

The safety ofthe participant is of primary importance, and risks of involvement in thetrial, in particular with added challenges due to COVID-19, should be weighedagainst anticipated benefit for the participant and society (ref: principle 2.2of ICH GCP).

受试者的安全是最重要的，应权衡参与试验对于受试者和社会的风险，尤其是COVID-19带来的挑战，以及预期的收益（参考：ICH GCP原则2.2）。

All decisionsto adjust clinical trial conduct should be based on a risk assessment by thesponsor (ICH GCP section 5.0). It is expected that the sponsor performs a riskassessment of each individual ongoing trial and the investigator of eachindividual participant and implements measures which prioritise subject safetyand data validity. In case these two conflict, subject safety always prevails.These risk assessments should be based on relevant parties' input and should bedocumented on an ongoing basis. It is important that sponsors in their riskassessment consider prioritisation of critical tasks in the clinical trial andhow these are best maintained.

调整临床试验的所有决定均应基于申办者的风险评估（ICH GCP第5.0节）。申办者应对每个正在进行的试验和每个受试者的研究者进行风险评估，并优先考虑实施以受试者安全和数据有效性的为前提的措施。在二者冲突的情况下，始终以受试者的安全为重。这些风险评估应基于相关方的意见，并应持续记录在案。重要的是，申办者在进行风险评估时应考虑临床试验中关键目标的优先级，以及如何最好地维护这些目标。

The sponsorshould reassess risks as the situation develops. This reassessment should alsobe documented.

申办者应根据情况的发展重新评估风险。重新评估也应记录在案。

It is possiblethat with the escalation of the pandemic, local circumstances lead to a localchange in risk assessment, therefore the need to implement additional measuresmay arise, and an investigator-driven risk assessment might be necessary (andcommunicated to the sponsor).

随着疫情升级，当地情况可能导致风险评估在当地发生变化，因此可能需要实施其他措施，并且有必要进行研究者主导的风险评估（并传达给申办者）。

Regardingparticipants enrolled in ongoing clinical trials who may be determined as beinga risk group for COVID-19 or who are in trials involving therapies which mayincrease such risk, the potential impact of COVID-19 on these patient groupsshould be carefully considered when deciding to start or continue such trials.

对于正在试验中的受试者，他们本身可能是 COVID-19 风险较大的人群，或者参与的治疗可能增加风险，在决定开始或继续进行此类试验时，申办者应仔细考虑 COVID-19 的潜在影响。

Communication with authorities

与当局沟通

Priority isgiven to any (new) clinical trial applications for the treatment or preventionof COVID-19 infection, and/or substantial amendment applications to existingclinical trials necessary as a result of COVID-19.

优先审核用于治疗或预防COVID-19感染的任何（新）临床试验申请，和/或由于COVID-19而必须对现有临床试验进行的重大修订的申请。

In case therisk assessment leads to actions that affect the trial as described below in a)and b), the relevant competent authorities and Ethics Committees must beinformed in accordance with the Directive 2001/20/EC and national laws:

当风险评估产生下述a)和b)中影响试验的行为时，则必须根据第2001/20 / EC号指令和国家法律告知相关主管部门和伦理委员会：

a) When a newevent is likely to have a serious effect on the benefit-risk balance of thetrial, it is possible that immediate actions are required by the sponsor andinvestigator to protect the subjects against immediate hazard. These, urgentsafety measures may be taken without prior notification, but the informationneeds to be provided ex post to the National Competent Authority (NCA) and theEthics Committee as soon as possible (EC 2010/C82/01; 3.9). In thiscommunication, the sponsor is expected to provide adequate information on themeasures taken and the plan for further actions;

a）如果新事件可能对试验的利益风险平衡产生严重影响，则申办者和研究者可能需要立即采取行动，以保护受试者免于急性危害。可在没有事先通知的情况下采取紧急的安全措施，但是必须尽快将信息提供给国家主管部门（NCA）和伦理委员会（EC 2010 / C82 / 01; 3.9）。在沟通中，申办者应提供有关采取的措施和进一步行动计划的充分信息；

b) If changesare likely to affect the safety or well-being of the participants and/or thescientific value of the trial, but do not require immediate action from sponsoror investigator, it should be possible to submit them as substantial amendmentapplications. Sponsors are encouraged to take into account the limited capacityof assessors, and submit only high quality, complete applications containingonly the necessary changes. Over-reporting should be avoided (Art. 11b ofDirective 2001/20/EC CT-1section3.9).

b）如果更改可能会影响受试者的安全或生命健康和/或试验的科学价值，但并不需要申办者或研究者立即采取行动，则应将其作为重大修订申请提交。申办者应考虑到评估者能力有限，并且仅提交高质量、完整的申请，其中仅包含必要的更改。应避免过度报告（条款2001/20 / EC CT-1 章节3.9中的11b部分）。

Unlessotherwise advised by relevant authorities, it is recommended to mark anycontact clearly with 'COVID-19' in the subject field.

除非相关当局另有建议，否则建议在主题字段中填写“ COVID-19”并清晰标记所有联系人。

Agreement with and communication to sites

与试验机构达成协议并进行沟通

Changes totrial conduct should be agreed with and communicated clearly to investigatorsites. To support implementation by sites, it is important that changes andlocal implications are made clear, including marking of changed documents withtrack changes. Agreements may be documented as e-mail exchange.

试验实施变更应得到同意，并明确传达给研究者所在机构。为了方便试验机构实施，应该明确更改的内容以及对当地的影响，包括使用修订痕迹修改文档。可通过电子邮件往来记录达成的共识。

Changes to informed consent

知情同意书的变更

Sponsors shouldbe mindful of the current pressure on the medical profession and shouldcarefully assess the pertinence of adding new subjects in ongoing clinicaltrials. Absolute priority should be given to clinical trials on treatments forCOVID-19 and COVID19-COVID-19related illnesses, or trials on serious diseaseswith no satisfactory treatment option. In case a sponsor plans to initiate atrial aiming to test new treatments for COVID-19, advice should be sought onalternative procedures to obtain informed consent, as it is likely that thephysical consent cannot leave the isolation room, and therefore is notappropriate as trial documentation.

申办者应警惕医学界的压力，并应仔细评估正在进行的临床试验中增加新受试者的相关性。必须优先考虑有关COVID-19和COVID-19相关疾病的临床试验，或目前无有效治疗手段的严重疾病的试验。如果申办者计划启动测试COVID-19新疗法的试验，则应寻求替代性手段以获得知情同意书，因为同意书可能无法离开隔离地区，因此不合适作为试验记录。

In case ofemergency situations, when trial participants are incapable of giving theirinformed consent (for example because they are under intensive medical care),sponsors shall adhere to the provisions set out in the Directive (Art 5) and by national regulations. Informed consent of these patients ortheir representatives will need to be acquired later, as soon as feasible, ifdeferred consent in emergency situations is permitted under national law.

在紧急情况下，如果受试者无法给出知情同意书（例如，处于重症监护），申办者应依从《指令》（第5条）和国家法规中的规定。在根据国家法律允许在紧急情况下推迟同意时，需要在可行的情况下尽快获得这些患者或其代表的知情同意。

There may be aneed to re-consent already included trial participants. However, avoid the needfor trial participants to visit investigator sites for the sole purpose ofobtaining re-consent. If re-consents are necessary for the implementation ofnew urgent changes in trial conduct (mainly expected for reasons related toCOVID-19), alternative ways of obtaining such re-consents should be consideredduring the pandemic e.g. contacting the trial participants via phone orvideo-calls and obtaining oral consents supplemented with email confirmation.Any consent obtained this way should be documented and confirmed by way ofnormal consent procedures at the earliest opportunity when the trialparticipants will be back at the regular sites

已经参与试验的受试者可能需要重新签署同意书。但是，应避免受试者仅为了重新签署知情同意而特意访视研究者机构。如新的紧急变更试验行为需要重新取得同意（大部分是出于与COVID-19相关的原因进行变更），则应在大流行期间考虑用代替手段获得此类再次同意，例如通过电话或视频电话与受试者联系，获得口头同意并附上电子邮件确认。对于以此种方式获得的知情同意应记录在案，当受试者可以返回日常试验机构时，应该尽早通过常规程序进行确认。

Any validatedand secure electronic system already used in the trial for obtaining informedconsent can be used as per usual practice and if in compliance with nationallegislation.

在符合国家法律的规定的情况下，为获得知情同意书，任何试验中已经使用、经过验证且安全的电子系统，都可以作为常规手段使用。

Changes in the

distribution of the IMP

试验用药品分发的变化

Changes in thedistribution of the IMP may be necessary to remove avoidable visits to sitesand to provide the patients with needed treatments. Sponsors must assess therisks relating to the product and consider any alternative shipping and storagearrangements.

可能有必要更改试验用药品的分发，以避免访视试验机构，并为患者提供所需的治疗。申办者必须评估与产品有关的风险，并考虑替代性的运输和储存方式。

Such measuresraise various practical considerations, including whether the IMP isappropriate for administration and general storage at the trial participant'shome, how the stability of the product will be maintained during transit(especially for cold chain product), how safe custody of product will beensured and how IMP accountability and the evaluation of compliance totreatment (if appropriate) will be managed.

此类措施需要进行各种实际考虑，包括试验用药品是否适合给药和一般存放在受试者家中，在运输过程中如何保证产品的稳定性（尤其是对于冷链产品），如何确保安全保管产品，如何对清点试验用药品和评估治疗依从性（如适用）进行管理。

The overridingobjective of all changes in distribution is to provide the participatingpatients with the IMP and other medications categorised as non-IMPs as neededaccording to the trial protocol to ensure the right, safety and well-being oftrial participants as well as the integrity of the clinical trial.

对于所有分发变化，首要目标是为了给受试者提供试验用药品和其他非试验用药品所需药物，以确保受试者的权利、安全、生命健康，以及临床试验的完整性。

Changes in distribution of IMP may include:

试验用药品分发变化可能包括：

•In case of urgent shortage of IMP atsome sites or transfer of trial participants from one site to another clinicaltrial site, there might be a need to potentially re-distribute the IMP betweensites in accordance with GMP annex 13 (section 47). This should only beconsidered in cases where a direct distribution of the IMP to a trial site bythe usual distributor is not possible or in the exceptional circumstance wherea trial participant is transferred from one site to another. Sponsors shouldassess whether sites can handle and control such a re-distribution process,especially in case of restricted conditions for storage such as the need forspecific conditions other than room temperature (e.g. +2-8° C). Re-distributionshould follow a written procedure established in cooperation with the QualifiedPerson or the person responsible for distribution of the IMP, and sites shouldbe provided with sufficient information to ensure that the process can beperformed securely. Associated records should be included in the transfer;

•当某些机构试验用药品出现突发性短缺，或受试者从一个临床试验机构转移至另一个研究机构时，可能需要根据GMP附件13（第47节）中的要求潜在地重新分发各试验机构间的试验用药品。应只在下列情况下才考虑这一操作：无法通过通常的分销商将试验用药品直接分发到试验机构，或是受试者从一试验机构转移到另一试验机构的特殊情况。申办者应评估该机构是否可以处理和控制重新分发过程，尤其是存储条件十分苛刻的情况，如需要非室温（例如，+ 2-8°C）的特定条件。重新分发应遵循书面程序，建立与授权人或试验用药品分发负责人的合作，并且应向试验机构提供足够的信息以确保可以安全地执行这一过程。相关记录应保存；

•In line with the reduction of physicalsite visits, we foresee that there will be a need for delivery of the IMPdirectly to trial participants during the COVID-19 pandemic to avoid that thetrial participant has to reach the site with the consequent risk of spreading/acquiringinfection. The delivery is generally expected to happen from investigator sites(e.g. via hospital (or other) pharmacies as applicable) to trial participants;

•为了减少实地访视，我们预测到在COVID-19疫情大流行期间有必要将试验用药品直接交付给受试者，避免受试者前往试验机构，增加传播/被感染病毒的几率。一般情况下，药品是在试验机构（例如，医院（或其他医疗机构）、药房）交付给受试者；

•Direct from sponsor to trialparticipant IMP delivery is accepted in a few member states under thisemergency situation.The sponsor should check the NCA guidance regarding thepossibility of direct sponsor to trial participant shipment, as it is likelythat such measures can only be implemented under specified conditions(e.g.agreement with sites, dedicated couriers with procedures to only allow deliverydirectly to a trial participant or his/her carer, solid shipment and receiptprocedures, informed consent provisions if necessary for the sponsor's thirdparty to handle personal information etc.),and for a limited period.

•在此类突发疫情之下，一些成员国采纳了由申办者直接将试验用药品交付受试者的方式。申办者应根据NCA指南确认申办者直接交付受试者方式的可行性，因为很有可能这些措施只能在特定条件下方可实施（例如，与试验机构达成协议，根据规程指定专门的快递员并负责直接送至指定的受试者及照看人，可靠的交付和收据程序，必要的知情同意条款以保证申办者的第三方机构处理个人信息，等等），且在一定期限内。

Alternativeshipping and storage arrangements should not compromise the treatment blinding.

变更运输和存储安排不应违背治疗盲法设计。

Changes tomonitoring

监查的变更

Certain sponsoroversight responsibilities, such as monitoring and quality assurance activitiesneed to be reassessed and temporary, alternative proportionate mechanisms ofoversight may be required. The extent of on-site monitoring, if it remainsfeasible, should take into account national and local restrictions, the urgency(e.g. source data verification can often be postponed) and the availability ofsite staff, and should only be performed as agreed with investigator sites. Theburden of the introduction of any alternative measures for the site staff andfacilities should also be considered in order to strike an acceptable balancebetween appropriate oversight and the capacity of and possibilities at thesite.

需要重新评估某些申办者的具体监查职责，例如监查和质量控制，可能需要临时的、可替代的监督机制。如果现场监查仍然可以运行，其监查范围应当充分考虑国家和地方法规的限制，紧急状态（例如，源数据核查通常可以推迟）以及现场工作人员的可用性，并且仅应在研究者所在试验机构同意的情况下进行。还应考虑采取任何替代性措施给试验机构工作人员和设备带来的额外负担，以确保在适当的监督与试验机构承载能力之间取得可接受的平衡。

Possible temporary, alternative measures could include:

临时、替代性方法可能包括：

•Cancelling of on-site monitoring visitsand extending of the period between monitoring visit;

•Implementing phone and video visits(without unnecessarily increased burden to the investigator site and takinginto account trial participant integrity);

•Adapting the on-site monitoring planwhen it is impossible to follow, supplementing it with (additional/increased)centralized monitoring and central review of data if possible and meaningful.

•取消现场监查访视，及延长监查访视的间隔；

•进行电话和视频访视（避免为试验机构人员增加不必要的负担，同时考虑到受试者的完整性）；

•无法遵循原有计划时需改变现场监查访视计划，在可行且有意义的前提下，可将（附加/增加）中央监查和中央数据审评作为补充。

Results ofadjusted monitoring/review measures should be reported to the sponsor inmonitoring reports and in the clinical study report.

调整后的监查/审评措施结果应在上报给申办者时完整体现在监查报告和临床研究报告中。

It is essentialthat robust follow-up measures are planned and ready to be implemented when thesituation is normalised. This should likely include increased on-sitemonitoring for a period that is sufficient to ensure that the impact of thereduced monitoring could be rectified and problems resolved or properly documentedfor reporting in the clinical study report.

在情况恢复正常后，计划并准备好强有力的后续跟进措施至关重要。措施包括增加现场监查时间，以确保纠正先前减少监查的影响，并解决问题或在临床研究报告中适当地把问题记录下来。

So-calledremote source data verification (e.g. providing sponsor with copies of medicalrecords or remote access to electronic medical records) is currently notallowed in most member states as it might infringe trial participants' rights.In addition, provision of redacted/ de-identified pdfs files will not beacceptable as it puts disproportionate burden on site staff.

目前，大多数成员国不允许采用所谓的“远程源数据验证”（例如，向申办者提供病历复印件或远程查阅电子病历），因为这可能会损害受试者的权利。此外，提供已修改的/去标识的PDF文件也不可接受，因为这会大量增加试验机构工作人员的负担。

Nevertheless,since the coronavirus emergency situation and containment measures are likelyto last for a prolonged period, several NCAs have started to look intopossible, temporary solutions related to remote access and conditions for such,providing that methods can be used that restricts access to trial participantrecords, in line with the principles of necessity and proportionality. Thisshould however also be clarified with other relevant authorities in this area(such as, without limitation, Ethics Committees and data protection agencies)and is consequently not allowed unless a member state has given specificguidance allowing this.

然而，鉴于冠状病毒突发疫情及其防控措施可能会持续很长一段时间，一些国家主管机关已开始研究与远程访问及其条件相关的一些可能的临时解决方案，如有限制地查阅受试者的记录，并符合必要性和相称性原则。此外还应当向该领域其他相关机构（例如但不限于伦理委员会和数据保护机构）进行澄清，并最终在成员国颁布具体指南许可的前提下采取这一方式。

Protocoldeviations

临床试验方案偏离

We acknowledgethat the COVID-19 situation is likely to introduce more protocol deviationsthan normal. We expect that the sponsor escalates and manages such protocoldeviations in accordance with their standard procedures. A proportionateapproach will be taken by the GCP inspectors when such deviations are reviewedduring inspections, in particular where the best interest of the participant ismaintained, and the participant is not put at risk.

我们认为COVID-19疫情可能会导致更多的与原有方案偏离的情况。希望申办者能够按照其标准方案进行上报、管理。特别是在保护受试者利益，避免给受试者带来风险的情况下，如果GCP监察员在检查过程中发现了方案偏离，监察员应相应采取适当方法解决。

An increase inprotocol deviations in relation to the COVID-19 situation will in itself nottrigger the actions required by GCP § 5.20. They will however need to beassessed and reported in the clinical study report, following ICH E3.

与 COVID-19 情况相关的方案偏离的增加，本身不会造成 GCP § 5.20中要求的行为，但是应根据 ICH E3要求在临床研究报告中评估和报告。

Reimbursementof exceptional expenses

特殊费用的报销

Taking intoaccount this exceptional situation, if, in order to implement urgent measuresfor the protection of participants involved in a clinical trial, expenses mayarise which may be borne initially by the participants, these should typicallybe compensated subsequently by the sponsor via the investigator. If additionalfinancial compensation is provided to sites/investigators (e.g. to cover thecost of using couriers for IMP delivery), this needs to be documented andperformed according to national legislation. Handling of reimbursement of suchexpenses should follow national legislation and/or guidance.

考虑到疫情特殊情况，若为保护临床试验受试者执行的紧急措施，产生的费用最初可能由受试者承担，然后应由申办者通过研究者予以报销补偿。如果需向试验机构/研究者提供额外的经济补偿（例如支付寄送试验用药品的快递费用），则需要依据国家法规执行。此类费用的报销应遵循国家法律和/或相关指南。

Initiation ofnew trials aiming to test new treatments for COVID-19

启动研究COVID-19新疗法的新临床试验

The MemberStates support the submission of large, multinational trial protocols for theinvestigation of new treatments for COVID19[2].

成员国需支持关于COVID-19的新疗法研究的大型的跨国试验方案 。

In addition,sponsors are encouraged to consider the submission of such applications for anaccelerated Voluntary Harmonisation Procedure[3] (VHP) assessmentwhen possible. In order to avoid or minimise delays due to the harmonisedreview, sponsors are recommended to prospectively contact the proposed Ref NCAto explore the feasibility of an accelerated VHP (plus) process.

此外，鼓励申办者考虑提交关于加快“自愿协调程序（VHP）”评估的申请。为避免或减少因统一审核造成的延误，建议申办者预先联系相关主管机关，探讨加速VHP流程的可行性。

It should benoted that the developers of medicines or vaccines are invited to contact EMAas soon as possible with information about their proposed development by emailing 2019-n [e-mail] provides a full fee waiver and a fast-track procedure forscientific advice[4].

请注意，药物或疫苗的开发人员应尽快与EMA联系

（联系邮箱：2019-n [e-mail]），就其拟开发药品的信息进行沟通。EMA将提供免费的科学咨询，并予以快速审评程序。

最后，在此特别感谢张丹博士在本文翻译过程中提供的帮助与指导

张丹

方恩（天津）医药发展有限公司董事长兼CEO

中国医药创新促进会药物研发专业委员会、创新研发服务专业委员会副主任委员

[1]The word « participant » is used in this text as a synonym for the term “subject”,defined in Directive 2001/20/EC as an individual who participates in a clinicaltrial as either a recipient of the investigational medicinal product or acontrol”.

[1]在本文中，“参与者”一词是“受试者”一词的同义词，在指令2001/20 / EC中定义为“参加临床试验的人是接受研究药物或对照的人”。

[2]https://www.ema.europa.eu/e n/n ews/call-pool-research-resources-large-multi-centre-multi-arm-cli nical-trials-gen erate-sou nd-evide nee

[3]https://www.hma.eu/fileadmin/dateie n/Huma n Medic in es/01-

About HMA/Working Groups/CTFG/2016 06 CTFG VHP guidaneefor sponsor v4.pdf

[4]https://www.ema.europa.eu/en/n ews/covid-19-developers-medic in es-vacc in es-be nefit-free-scientific-advice